Overview

* PepGen ( PEPG ) Q3 net loss narrows to $18 mln from $21.4 mln in 2024

* Company raised $115 mln, extending cash runway into 2H 2027

* FREEDOM-DM1 study shows highest mean splicing correction in DM1 patients

Outlook

* PepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026

* Company plans to initiate 10 mg/kg dosing in FREEDOM2 in Q1 2026

* PepGen's ( PEPG ) cash runway extended into second half of 2027

Result Drivers

* Research and Development Expenses

were $13.4 million for the three months ended September 30, 2025, compared to $17.7 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.52

Q3 Net -$18.03

Income mln

Q3 $18.65

Operatin mln

g

Expenses

Q3 -$18.65

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for PepGen Inc ( PEPG ) is $9.00, about 48.3% above its November 11 closing price of $4.65

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)